Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 7:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1249–1272 of 21,010 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Immune System Disorders Clear all
Terminated Phase 1 Interventional

Safety and Efficacy Study of Tenalisib (RP6530) in Combination With Pembrolizumab in Relapsed or Refractory cHL

NCT03471351
View directory record Official record
Conditions
Classical Hodgkin Lymphoma
Interventions
Tenalisib, Pembrolizumab
Drug · Biological
Lead sponsor
Rhizen Pharmaceuticals SA
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Chicago, Illinois • Detroit, Michigan • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 27, 2019 · Synced Oct 31, 2026, 7:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Effects of Advantage 24 on the Rectum

NCT00000929
View directory record Official record
Conditions
HIV Infections
Interventions
Nonoxynol-9
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older · Male only
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 1999
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 31, 2026, 7:55 PM EDT
Completed Phase 3 Interventional Results available

SWOG-9704 Chemoradiotherapy and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma

NCT00004031
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab, CHOP regimen, carmustine, cyclophosphamide, doxorubicin hydrochloride, etoposide, prednisone, vincristine sulfate, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
15 Years to 65 Years
Enrollment
397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2013
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Oct 31, 2026, 7:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Mhealth for Pre-exposure Prophylaxis Adherence by Young Adult MSM

NCT04233931
View directory record Official record
Conditions
Hiv
Interventions
PrEP medication adherence mobile app
Behavioral
Lead sponsor
Environment and Health Group, Inc.
Industry
Eligibility
20 Years to 29 Years · Male only
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 31, 2026, 7:55 PM EDT
Terminated Phase 2 Interventional Results available

Ivabradine in the Management of Cardiac Autonomic Dysfunction Associated With Thoracic Radiation Therapy.

NCT03137537
View directory record Official record
Conditions
Lymphoma, Autonomic Imbalance, Cancer Survivorship
Interventions
Ivabradine, Placebo Oral Tablet
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 10, 2022 · Synced Oct 31, 2026, 7:55 PM EDT
Terminated No phase listed Observational

Pharmacokinetics of Systemic Anti-Cancer Therapies in the Cerebrospinal Fluid (CSF) of Patients With Advanced Cancer

NCT02580045
View directory record Official record
Conditions
Metastatic Cancer Patients on an Anti-cancer Therapy, Advanced Cancer, Brain Metastasis
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 28, 2018 · Synced Oct 31, 2026, 7:55 PM EDT
Completed Phase 3 Interventional

A Comparison of Valganciclovir and Ganciclovir in the Treatment of Cytomegalovirus (CMV) of the Eyes

NCT00002377
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Valganciclovir, Ganciclovir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
14 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
15
States / cities
Irvine, California • La Jolla, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated May 17, 2017 · Synced Oct 31, 2026, 7:55 PM EDT
Active, not recruiting Phase 1 Interventional

A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma

NCT03091257
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Dabrafenib, Trametinib
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
2
States / cities
Boston, Massachusetts • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 31, 2026, 7:55 PM EDT
Completed Not applicable Interventional Results available

Androgen Effects in HIV-infected Women

NCT00095212
View directory record Official record
Conditions
HIV Infection
Interventions
1 Transdermal Testosterone (Patch), 2 Placebo Patch
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 14, 2010 · Synced Oct 31, 2026, 7:55 PM EDT
Recruiting Not applicable Interventional

Assessing DCog Short for Neurotoxicity in CAR-T

NCT07403812
View directory record Official record
Conditions
Neurotoxicity, Neurotoxicity Syndromes, Hematologic Malignancy, Immune Effector Cell Associated Neurotoxicity Syndrome
Interventions
DCog Short
Behavioral
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 31, 2026, 7:55 PM EDT
Completed Phase 3 Interventional

PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial

NCT05511922
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
KVD900 600 mg, Drug: KVD900 300 mg
Drug
Lead sponsor
KalVista Pharmaceuticals, Ltd.
Industry
Eligibility
12 Years to 17 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
20
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • San Diego, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 31, 2026, 7:55 PM EDT
Completed Not applicable Interventional Results available

Accelerated Transcranial Magnetic Stimulation (TMS) for Smoking Cessation in People Living With HIV/AIDS (PLWHA)

NCT05295953
View directory record Official record
Conditions
Hiv, Tobacco Smoking
Interventions
TBS, Sham TMS
Device
Lead sponsor
Gopalkumar Rakesh
Other
Eligibility
18 Years to 60 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Oct 31, 2026, 7:55 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Pilot Study to Assess microRNA Biomarkers in Early and Later Stage Multiple Sclerosis

NCT01737372
View directory record Official record
Conditions
Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Clinically Isolated Syndrome
Interventions
Not listed
Lead sponsor
John F. Foley, MD
Other
Eligibility
18 Years to 68 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 9, 2016 · Synced Oct 31, 2026, 7:55 PM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis

NCT01732757
View directory record Official record
Conditions
Conjunctivitis, Allergic
Interventions
Alcaftadine 0.25%, Olopatadine 0.2%, dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
Drug
Lead sponsor
Allergan
Industry
Eligibility
10 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 14, 2014 · Synced Oct 31, 2026, 7:55 PM EDT
Terminated Phase 1 Interventional Results available

Safety of Bryostatin in Patients With MS

NCT06190912
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Bryostatin 1
Drug
Lead sponsor
Robert Fox
Other
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 31, 2026, 7:55 PM EDT
Completed No phase listed Observational

Historical Data Analysis of Hematological Remission and Survival in Adults With R/R Acute Lymphoblastic Leukemia

NCT02003612
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia
Interventions
Not applicable - observational study
Other
Lead sponsor
Amgen
Industry
Eligibility
15 Years and older
Enrollment
2,373 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Boston, Massachusetts • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Oct 31, 2026, 7:55 PM EDT
Recruiting Phase 1 Interventional

Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)

NCT05862012
View directory record Official record
Conditions
Relapsed/Refractory Multiple Myeloma
Interventions
ISB 2001
Drug
Lead sponsor
Ichnos Sciences SA
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
10
States / cities
Palo Alto, California • Miami, Florida • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 31, 2026, 7:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Using an mHealth App to Transition Care of Type-1 Diabetes From Parents to Teens

NCT03436628
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Adolescent Behavior, Parent-Child Relations, Communication
Interventions
MyT1DHero
Device
Lead sponsor
Michigan State University
Other
Eligibility
10 Years to 15 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
East Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 31, 2026, 7:55 PM EDT
Terminated Phase 1 Interventional Results available

DS-3201b for Acute Myelogenous Leukemia (AML) or Acute Lymphocytic Leukemia (ALL)

NCT03110354
View directory record Official record
Conditions
Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute
Interventions
DS-3201b
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
6
States / cities
Boston, Massachusetts • Ann Arbor, Michigan • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2024 · Synced Oct 31, 2026, 7:55 PM EDT
Terminated No phase listed Observational

Assessing the Induction of Long-term Immune Regulation Following Treatment With Lemtrada® (Alemtuzumab).

NCT03647722
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Assessment of leukocyte function.
Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 31, 2026, 7:55 PM EDT
Completed Phase 3 Interventional

Two-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome

NCT05350072
View directory record Official record
Conditions
Sjogren Syndrome
Interventions
VAY736, Placebo
Biological · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
13
States / cities
Van Nuys, California • Tamarac, Florida • Indianapolis, Indiana + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 31, 2026, 7:55 PM EDT
Suspended Not applicable Interventional

Pedicle Osteotomy for Stenosis Trial

NCT03381677
View directory record Official record
Conditions
Lumbar Spinal Stenosis, Spondylolisthesis, Grade 1, Neurogenic Claudication
Interventions
Pedicle Lengthening Osteotomy with Altum® Device, Control
Device
Lead sponsor
Innovative Surgical Designs
Industry
Eligibility
40 Years to 80 Years
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Bryn Mawr, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Oct 31, 2026, 7:55 PM EDT
Completed Phase 1Phase 2 Interventional

Stem Cell Transplant for Patients With Blood Malignancy Using Donors and Less Toxic Chemotherapy With CAMPATH 1H

NCT00048412
View directory record Official record
Conditions
Myelodysplastic Disorders, Leukemia, Multiple Myeloma, Plasma Cell Dyscrasia, Lymphoproliferative Disorders
Interventions
FLUDARABINE, CAMPATH 1H, FK50, Stem Cell Collection and Infusion
Drug · Procedure
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 31, 2026, 7:55 PM EDT
Completed Phase 1 Interventional

Phase I Study of the Safety, Tolerance, and Pharmacokinetics of 9-[2-(Bispivaloyloxymethyl)Phosphonylmethoxyethyl]Adenine (Bis-POM PMEA; Adefovir Dipivoxil) in HIV-Infected Patients

NCT00002128
View directory record Official record
Conditions
HIV Infections
Interventions
Adefovir dipivoxil
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 60 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 31, 2026, 7:55 PM EDT